Chartered Trade Mark Attorney, Alexandra Nott explores some of the reasons that trade mark protection remains crucial in today’s business environment.
READ MORE
In this insight, Biotechnology partner Kit Wilkins reviews the US Supreme Court’s decision to Consider “Skinny Labels” in Generic Drug Patent Dispute. The decision could result in significant implications of generic medicines in the US.
READ MORE
In this insight, Holly Rocliffe from Dehns Biotechnology group explores the recently handed down decision in Otsuka Pharmaceutical Co Ltd v Sun Pharma ANZ Pty Ltd [2025] FCAFC 161[1], in which the Full Court of the Federal Court of Australia (Full Court) has ruled that patent term extension (PTE) is only available for patents which claim an active pharmaceutical ingredient (API).
READ MORE
The first decision from the UPC on sufficiency — handed down in the Amgen v. Sanofi case — provides the first clear guidance on how the court will address whether a patent’s disclosure is sufficient.
READ MORE
In this insight, Dehns Partner Rob Jackson and Conor Wilman from our Technology, Software and Engineering group explore the UPC’s Court of Appeal recent issues of two important decisions about how it will assess inventive step in patent cases.
READ MORE
The UK Intellectual Property Office (UKIPO) is consulting on possible changes to the UK design framework with the aims of improving design validity, simplifying the regime, and protecting emerging forms of design.
READ MORE
The G1/23 ruling from the European Patent Office marked a pivotal shift in how marketed products are treated as prior art, redefining the principles of reproducibility and disclosure across Europe. Dehns has collaborated with international patent experts to provide a global perspective on the ruling.
READ MORE
This decision concerned an application for provisional measures, in particular an anti-anti-suit injunction (‘AASI’), by Avago Technologies International Sales Pte. Limited against the defendant Realtek Semiconductor Corporation
READ MORE
A Supplementary Protection Certificate (SPC) is a form of intellectual property that can extend the protection of patented active ingredients present in pharmaceutical or plant protection products by up to five years.
On 14 November 2018 the UK Supreme Court (SC) handed down its decision in Warner-Lambert Company LLC v Generics (UK) Ltd t/a Mylan and Actavis, which includes a majority judgment and interesting dissenting ones.
European patent law differs in some significant aspects from the law in other countries, in particular the United States. This note sets out some important features of European patent law to remember when preparing patent applications for Europe.
If you have identified an interesting opportunity for a research or development collaboration and are discussing a potential agreement, then Intellectual Property (IP) is one of the key factors that will need your consideration. This article provides clear, practical guidance on how to approach the key IP issues that can arise before, during and after such collaborations.
European patent law differs in some significant aspects from the law in others countries, in particular the United States. Our briefing note on “European Practice for Overseas Attorneys” discusses some more general issues to bear in mind when drafting. This note provides some more detailed tips on drafting European patent applications so that some common problems can be avoided.
Supplementary Protection Certificates (SPCs) are a form of patent term extension.
Can we apply for patent protection for our new app?
We’re about to launch a unique software product that correlates the weather observations from multiple satellites. It’s a niche market and we’re confident that there’s no other program that interleaves the data as quickly or efficiently as the algorithms that we’ve developed. The results can be downloaded and displayed via a smart phone app.
The examination procedure in European patent applications is primarily conducted in writing. However, all applicants have the right to be heard in Oral Proceedings. This can be a very useful procedure if the progress made in written correspondence is unsatisfactory. This briefing note provides an overview of such Oral Proceedings.
The responsibility for examining European patent applications rests with an Examining Division. Once the Examining Division is satisfied that an application complies with all the requirements of the European Patent Convention (EPC), the applicant is notified of the intention of the European Patent Office (EPO) to grant a patent.
We have put together a handy list of organisations that provide business support relating to a variety of issues ranging from intellectual property (IP) to funding. Many of the resources can be accessed free of charge by anyone, but some of the programmes and funding opportunities are only available to UK businesses.
Subscribe here for updates on IP news, events and webinars.
|